Shervin Pishevar Sees A Major Storm Approaching The Economy

There are many people that are under the impression that Bitcoin is dying, but according to Shervin Pishevar, they couldn’t be more wrong. While Bitcoin and other cryptocurrencies may have experienced a significant drop in price, he doesn’t believe that it will take very long for the value to rebound. He talked about Bitcoin and other topics affecting the economy in a recent Tweetstorm that spanned around 21 hours and marked his return to social media.

Shervin Pishevar, a major investor of Uber, is cautioning the world that the economy in the United States is about to face a major financial storm that could have prevented. With recent drops in the stock market, many people who originally dismissed his claims are taking a second look and are questioning if they are that far off from the truth. The issues that he sees taking a toll on the economy here include inflation, isolationism, and many more.

The state of the United States’ infrastructure has been a topic of conversation for many years now and Shervin Pishevar is predicting that it will get worse. Politicians are telling the people that these projects are just too big to complete quickly and that they must have patience as bridges and other important infrastructure are crumbling. Private firms like the Hyperloop are proving that these claims are necessarily true. Other examples include China where they were able to construct an entire train station in a matter of hours. The capabilities of other countries and private firms have many, including Shervin Pishevar, questioning why we are having these problems and why seemingly little is being accomplished to fix them.

Along with our bridges crumbling, he sees Silicon Valley as soon to be imploding in on itself. There are just a few companies that have control over the area and Shervin Pishevar predicts that they will soon be losing their Monopoly as they continue to lose the trust of their users and customers. While originally Silicon Valley was a physical place, it has become more of a movement that is taking place throughout the United States and the rest of the world.

http://summit.vanityfair.com/speakers/shervin-pishevar

Sahm Adrangi Is Onto Another Biotech Firm, Proteostasis, Calling Out Their New Drug Results

Kerrisdale Capital issued a negative report last week on the biotech firm, Proteostasis. Proteostasis recently made claims of developing a new drug for cystic fibrosis patients that is able to increase lung performance dramatically. Though the data they have presented is not very good and they have been highly transparent in their testing. This is what urged Sahm Adrangi to do some digging on the company, allowing Kerrisdale analysts to go over the data. Sahm Adrangi is a high-profile investor that has tackled other problem companies in the past and to great success actually. His reputation is good and many in the business world are ready to follow his lead, especially other investors to his successful track record.

This new drug that is being produced by Proteostasis had an extremely small sample size, consisting of just four individuals. For a disease like cystic fibrosis, claiming to have made a breakthrough is a big thing, and this is shattered when looking at the true data, which isn’t in good shape to begin with. According to Sahm Adrangi, Proteostasis’ has very messy data that cannot be understood easily. There results that have announced aren’t even accurate in their own data. With a sample size of four patients, results are skewed and possible just placebo. For a biotech company, offering data that has no actual information or results to be seen is a very bad thing. Whether its due to poor testing or bad management, either way, it’s shady for the business.

Sahm Adrangi’s statements and the report issued by Kerrisdale has had a noticeable impact on Proteostasis already, causing their share value to dip more than 15 percent since the report was released. This also caused the biotech firm to sell nine million of their own shares to recoup money for their continued testing. With that said, Proteostasis currently has more than 70 percent of their stock value invested in their drug, which could prove fatal for the company if it is not effective for patients.

https://www.kerrisdalecap.com/firm/sahm-adrangi/